Tag Archives: Jason Mccarthy

Analysts’ Top Healthcare Picks: Atossa Genetics (ATOS), CTI BioPharma (CTIC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atossa Genetics (NASDAQ:ATOS) and CTI BioPharma (NASDAQ:CTIC) with bullish sentiments. Atossa Genetics (ATOS) Maxim Group analyst Jason McCarthy maintained a Buy rating

Analysts Offer Insights on Healthcare Companies: Mesoblast Ltd (NASDAQ: MESO) and Pfizer (NYSE: PFE)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mesoblast Ltd (NASDAQ:MESO) and Pfizer (NYSE:PFE) with bullish sentiments. Mesoblast Ltd (MESO) Maxim Group analyst Jason McCarthy assigned a Buy rating to

Analyst Explains Why They Upgraded Their Buy Rating on ContraVir Pharmaceuticals Inc

In a report released today, Jason McCarthy from Maxim Group upgraded ContraVir Pharmaceuticals Inc (NASDAQ: CTRV) to Buy, with a price target of $3. The company’s shares closed yesterday at $1.18, close to its 52-week low of $1.15. McCarthy commented:

Veru Inc Initiated with a Buy at Maxim Group

Veru Inc (NASDAQ: VERU) received a Buy rating and a $10 price target from Maxim Group analyst Jason McCarthy today. The company’s shares closed yesterday at $1.95. McCarthy wrote: “We are initiating coverage of Veru Inc. with a $10 price

Why Did Maxim Group Downgrade Keryx Biopharma’s Stock?

In a report released today, Jason McCarthy from Maxim Group downgraded Keryx Biopharma (NASDAQ: KERX) to Hold. The company’s shares opened today at $4.55. McCarthy wrote: “Therapeutics announced a definitive merger agreement under which the companies will combine in an

Atossa Genetics Receives a Buy from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on Atossa Genetics (NASDAQ: ATOS) today and set a price target of $10. The company’s shares opened today at $2.40, close to its 52-week low of $2.30. McCarthy said: “Atossa announced